Breaking Finance News

TheStreet upgraded Corcept Therapeutics Incorporated (NASDAQ:CORT) to B in a report released today.

TheStreet has upgraded Corcept Therapeutics Incorporated (NASDAQ:CORT) to B in a report released on 05/22/2017.

Yesterday Corcept Therapeutics Incorporated (NASDAQ:CORT) traded 3.94% higher at $11.47. The company’s 50-day moving average is $15.54 and its 200-day moving average is $12.18. The last stock close price is down 49.41% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 1,582,183 shares of CORT traded hands, up from an average trading volume of 1,140,470

Recent Performance Chart

Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated has 52 week low of $6.11 and a 52 week high of $18.54 with a PE ratio of 90.55 and has a market capitalization of $0.

Brief Synopsis On Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *